Home page  |  Help  |  Clear
English  |  French
 Search  |  Categories  |  Titles A-Z  |  Countries  |  Compare countries  |  Index  
Full TOC
Expand Document
Expand Chapter
Preferences

close this bookNational Drug Policy - Nigeria (FMOH, WHO; 2005; 32 pages)
View the documentFOREWORD
View the documentACKNOWLEDGEMENTS
View the documentACRONYMS
View the document1.0 INTRODUCTION
View the document2.0 DEFINITION
View the document3.0 GOALS OF THE NATIONAL DRUG POLICY
View the document4.0 OBJECTIVES OF THE NATIONAL DRUG POICY
View the document5.0. TARGETS OF THE NATIONAL DRUG POLICY
close this folder6.0 STRATEGIES FOR IMPLEMENTING THE NATIONAL DRUG POLICY
View the document6.1 SELECTION OF DRUGS
View the document6.2 PROCUREMENT OF DRUGS
View the document6.3 DRUG REVOLVING FUND SCHEME
View the document6.4 PRICING POLICY
View the document6.5 DRUG STORAGE
View the document6.6 DRUG DISTRIBUTION
Open this folder and view contents6.7 RATIONAL DRUG USE
View the document6.8 DONATED DRUGS
View the document6.9 LOCAL DRUG PRODUCTION
View the document6.10 LEGISLATION
View the document6.11 INSPECTION OF DRUGS
View the document6.12 IMPORTATION AND EXPORTATION OF DRUGS
View the document6.13 REGISTRATION OF DRUGS
View the document6.14 PATENTS
View the document6.15 QUALITY ASSURANCE
Open this folder and view contents6.16 REGULATIONS FOR PRESCRIBING AND DISPENSING DRUGS
View the document6.17 PHARMACOVIGILANCE
View the document6.18 DRUG INFORMATION AND PROMOTION
View the document6.19 DRUG FINANCING AND AFFORDABILITY
Open this folder and view contents6.20 RESEARCH AND DEVELOPMENT
View the document6.21 HERBAL AND OTHER TRADITIONAL REMEDIES
View the document6.22 HUMAN RESOURCES DEVELOPMENT
View the document6.23 CONTROL OF VETERINARY DRUGS
View the document6.24 INTERNATIONAL COOPERATION
View the document6.25 MONITORING AND EVALUATION
 

6.1 SELECTION OF DRUGS

The objective of the drug selection process is to have a national list of drugs rationally chosen to satisfy the health care needs of the majority of the population. Such a list shall be revised regularly and shall form the basis of drug selection by primary, secondary and tertiary public health-care institutions. In this regard, the Federal Government shall take the following steps:

i A revised Essential Drugs List shall be published by the Federal Ministry of Health and made available to health professionals, state and local governments, primary, secondary and tertiary health institutions.

ii Drugs included on the list shall:

• be listed using generic or International Non-Proprietary Names (INN)
• be based on the health needs of the majority of the population
• have substantial safety and risk/benefit ratio with sufficient accumulated scientific data
• be registered by the national drug regulatory authority


iii As much as possible, formulations containing more than one active ingredient shall be avoided, unless one or more of the following criteria are met:

• the clinical condition justifies the use of more than one drug in a fixed combination, or
• two or more pharmacologically active ingredients are synergistically active in a product, or
• patient compliance is enhanced by the combination.


iv When two or more drugs are therapeutically equivalent or several drugs are available for the same indication, preference shall be given to products with the:

• most scientific research and clinical data
• most favourable pharmacokinetic properties
• best cost advantage
• best patient compliance
• most stable pharmaceutical dosage form for which appropriate storage facilities exist.


v The Essential Drugs List Review Committee shall update the list every four years.

vi Suggestions for amendment shall be made in writing on a prescribed form to the Federal Ministry of Health, justifying each suggested amendment. New drugs shall only be added to the list if sufficient scientific and clinical data are available to show that they offer distinct advantages over existing ones. Drugs on the list for which information becomes available that they no longer have a favourable risk/benefit ratio shall be withdrawn and replaced with safer alternatives.

vii The Essential Drugs List shall be used for:

• the procurement of drugs and their use in the public sector;
• prescribing drugs in the public sector;
• drug information to health care providers;
• the production of Standard Treatment Guidelines and a National Formulary;
• reimbursements on drugs in the National Health Insurance Scheme.

to previous sectionto next section

Please provide your feedback English  |  French